Method of treating atrophic vaginitis

A technology for atrophic vaginitis and vagina, which can be used in pharmaceutical formulations, female contraceptives, drug delivery, etc., and can solve problems such as increased risk of cancer

Inactive Publication Date: 2009-07-22
PEAR TREE WOMENS HEALTH CARE
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No drug candidate has emerged that meets the needs of women at increased risk of cancer who require the benefits of estrogen replacement to lead productive lives

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating atrophic vaginitis
  • Method of treating atrophic vaginitis
  • Method of treating atrophic vaginitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Example 1: Formulation of triphenylethylene derivatives in the form of suppositories

[0106] This example provides a formulation of a pharmaceutical composition for treating symptoms associated with atrophic vaginitis. Table 3 summarizes the various components and their respective amounts.

[0107] table 3

[0108] Tamoxifen Citrate 0.0200gm Silica gel 0.0150gm Matrix JAB: (fat matrix) 1.2485gm suppository volume filler 1.2835gm 0.0013gm of citric acid (0.1%) for pH adjustment

Embodiment 2

[0109] Example 2: Formulation of Triphenylethylene Derivatives in Cream Form

[0110] This example provides a formulation of a pharmaceutical composition for treating symptoms associated with atrophic vaginitis. Table 4 summarizes the various components and their respective amounts.

[0111] Table 4

[0112] Tamoxifen Citrate USP 0.0200gm Polyethylene glycol USP 0.0333ml JC Matrix (Matrix B and Matrix M)

Embodiment 3

[0113] Example 3: Formulation of triphenylethylene derivatives and progesterone in suppository form

[0114] This example provides a formulation of a pharmaceutical composition for treating symptoms associated with atrophic vaginitis. Table 5 summarizes the various components and their respective amounts.

[0115] table 5

[0116] Tamoxifen Citrate 0.0200gm progesterone 0.0300gm Silica gel 0.0150gm Matrix JAB: (fat matrix) 1.2215gm suppository volume filler 1.2865gm 0.0013gm of citric acid (0.1%) for pH adjustment

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.

Description

[0001] Cross references to related applications [0002] Pursuant to 35 U.S.C. §119, priority is claimed based on U.S. Provisional Application Nos. 60 / 810,715, filed June 2, 2006, and 60 / 917,800, filed May 14, 2007. The teachings of these referenced applications are hereby incorporated by reference in their entirety. field of invention [0003] The present invention relates to the use of triphenylethylene derivative compounds in novel pharmaceutical compositions for vaginal therapy for the treatment of symptoms associated with atrophic vaginitis. Background of the invention [0004] Atrophic vaginitis is a hormone-dependent disorder involving the lower urinary tract, reproductive tract, and pelvic floor. Generally, atrophic vaginitis becomes apparent during or after menopause, with symptoms intensifying with age. Symptoms involving genitourinary aging are due to loss of estrogen due to loss of follicles in the ovaries at menopause. This loss of estrogen can explain most o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61F6/06
Inventor J·A·乔勒特F·默梅尔施坦
Owner PEAR TREE WOMENS HEALTH CARE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap